Trial Profile
Prospective, randomized, open-label, clinical trial comparing the effects of olmesartan and amlodipine on blood pressure, endothelial function and makers for obesity/oxidative stress/chronic kidney diseases.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2011
Price :
$35
*
At a glance
- Drugs Amlodipine (Primary) ; Olmesartan medoxomil (Primary)
- Indications Essential hypertension
- Focus Biomarker; Pharmacodynamics
- 03 Sep 2011 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 01 Jun 2011 Results published in Hypertension Research.
- 01 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.